The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Indivior Pharmaceuticals Inc (Indivior) develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The company offers buprenorphine-based injectables for the treatment of opioid dependence, and buprenorphine-based injectable suspension for subcutaneous use, for the treatment of schizophrenia. It also offers a nasal spray for the treatment of opioid overdose reversal. Its pipeline portfolio encompasses products for substance use disorder and cannabis disorder. Indivior offers products in various formulations, including tablets, nasal sprays, transmucosal films, and injectables. The company offers its products across various countries globally. Indivior is headquartered in North Chesterfield, Virginia, the US.Indivior Pharmaceuticals Inc Key Recent Developments
- Mar 31, 2026: Cost-Impact Model Shows Monthly Injectable Buprenorphine Could Reduce Staffing Burdens in Correctional Facilities
- Jan 26, 2026: Indivior Announces Completion of Redomiciliation to the United States
- Oct 30, 2025: Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
- Jul 18, 2025: Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Filana Therapeutics Inc
- GW Pharmaceuticals Ltd
- Alkermes Plc
- Martindale Pharmaceuticals Ltd
- AstraZeneca Plc

